NLRP3 inflammasome in cancer and metabolic diseases

The NLRP3 inflammasome is a central operator in inflammation. Sharma and Kanneganti review the varied roles played by the NLRP3 inflammasome in cancer and metabolic diseases. The NLRP3 inflammasome is a multimeric cytosolic protein complex that assembles in response to cellular perturbations. This assembly leads to the activation of caspase-1, which promotes maturation and release of the inflammatory cytokines interleukin-1 beta (IL-1 beta) and IL-18, as well as inflammatory cell death (pyroptosis). The inflammatory cytokines contribute to the development of systemic low-grade inflammation, and aberrant NLRP3 activation can drive a chronic inflammatory state in the body to modulate the pathogenesis of inflammation-associated diseases. Therefore, targeting NLRP3 or other signaling molecules downstream, such as caspase-1, IL-1 beta or IL-18, has the potential for great therapeutic benefit. However, NLRP3 inflammasome-mediated inflammatory cytokines play dual roles in mediating human disease. While they are detrimental in the pathogenesis of inflammatory and metabolic diseases, they have a beneficial role in numerous infectious diseases and some cancers. Therefore, fine tuning of NLRP3 inflammasome activity is essential for maintaining proper cellular homeostasis and health. In this Review, we will cover the mechanisms of NLRP3 inflammasome activation and its divergent roles in the pathogenesis of inflammation-associated diseases such as cancer, atherosclerosis, diabetes and obesity, highlighting the therapeutic potential of targeting this pathway.

Automated summary

The NLRP3 inflammasome plays diverse roles in cancer and metabolic diseases, being involved in the release of inflammatory cytokines and inflammatory cell death upon activation. While inflammatory cytokines contribute to chronic inflammation and disease pathogenesis, fine tuning NLRP3 activity is crucial for maintaining cellular health.